top of page
An unprecedented therapeutic platform creating new hope for diseases with high unmet need.
Company Overview
Salvitus is pioneering an innovative therapy platform targeting the most deadly cancers, including colon, breast, and pancreatic cancers. This groundbreaking approach also holds significant potential for treating chronic autoimmune diseases such as Crohn’s Disease and Ulcerative Colitis. Our therapy is uniquely safe and non-toxic, delivered conveniently as an oral gummy formulation, and has extremely low costs of production.
Our Expertise
Metrics of Potential
$250B
total addressable market for lead therapies
48%
of all cancers can potentially be treated with Salvitus therapies
8
different Nobel Laureates worked with the Salvitus scientific cofounder
bottom of page